Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MIF | P14174 | 10/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | GLA | P06280 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.59 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30405545 | 1.00 | HSD17B3 (0.65) | HSD17B3POLBMIFMEN1KMT2A | |
| SCHEMBL15082511 | 0.89 | HSD17B3 (0.59) | HSD17B3POLBMIFMEN1KMT2A | |
| SCHEMBL29066603 | 0.86 | ESR2 (0.61) | HSD17B3POLBMIFMEN1KMT2A | |
| SCHEMBL10794446 | 0.86 | MAOA (0.62) | HSD17B3POLBKDM4EGLAGAA | |
| SCHEMBL27844746 | 0.86 | GAA (0.58) | HSD17B3POLBMIFMEN1KMT2A | |
| SCHEMBL6037595 | 0.85 | POLB (0.59) | HSD17B3POLBMIFMEN1KMT2A | |
| SCHEMBL16283606 | 0.85 | POLB (0.59) | HSD17B3POLBMIFMEN1KMT2A | |
| SCHEMBL28164061 | 0.85 | POLB (0.59) | HSD17B3POLBMIFMEN1KMT2A | |
| SCHEMBL4527127 | 0.85 | HSD17B3 (0.55) | HSD17B3POLBMIFMEN1KMT2A | |
| SCHEMBL29913658 | 0.84 | HSD17B3 (0.58) | HSD17B3POLBMIFMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174281-B1 | Modified nucleotides and uses thereof | Singular Genomics Systems, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | Technische Universität Berlin (DE) | 2019-06-04 | — | — | US | disclosed |
| WO-2017179018-A1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2017-10-19 | — | — | WO | disclosed |
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-2968308-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | Shire Human Genetic Therapies, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159637-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20120004257-A1 | NOVEL COMPOUNDS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| EP-0111746-B1 | SULFONIC-ACID ESTERS OF HYDROXYCOUMARINES, THEIR PREPARATION AND MEDICINES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1987-09-16 | — | — | EP | disclosed |
| US-4618622-A | ANTIDEPRESSANTS, ANTIALLERGENS | BASF AKTIENGESELLSCHAFT (DE) | 1986-10-21 | — | — | US | disclosed |
| EP-0111746-A2 | Sulfonic-acid esters of hydroxycoumarines, their preparation and medicines containing them | BASF Aktiengesellschaft (DE) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | MB, ALB, BCAT2 | HSD17B3 3924/4885POLB 305/4885MIF 1093/4885 |
| US-20120004257-A1 | NOVEL COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | HSD17B3 950/4885POLB 1049/4885MIF 2339/4885 |
| US-11174281-B1 | Modified nucleotides and uses thereof | NUDT1, RNMT, ADAR | HSD17B3 4788/4885POLB 88/4885MIF 3412/4885 |
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | BDKRB2, BDKRB1, HRH2 | HSD17B3 1366/4885POLB 3550/4885MIF 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.